Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the availability of Maraviroc to patients with progressive multifocal leukoencephalopathy.

We are informed by NHS England and NHS Improvement that it does not commission Maraviroc for progressive multifocal leukoencephalopathy as there is currently insufficient evidence to support its use in this condition.

NHS England and NHS Improvement have published do not commission policy for ‘Natalizumab-induced progressive multifocal leukoencephalopathy in relation to immune reconstitution inflammatory syndrome in multiple sclerosis.’

Due to a lack of evidence and as it is considered experimental, it is not currently commissioned for this indication.

Further information is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2018/03/maraviroc-for-ms-urgent-policy-statement.pdf